Fasting Mimicking Diet Improves Chemotherapy Effectiveness and Reduces Side Effects

The fasting mimicking diet emerged from efforts to better define the dose-response curve for beneficial effects resulting from a reduced calorie intake. Fasting is beneficial, calorie restriction is beneficial, but where are the dividing lines? How much food can one eat and still obtain near all of the benefits of fasting? As a result of this work, the fasting mimicking diet has undergone clinical testing in cancer patients. Numerous benefits have been demonstrated, and the paper here is an example of the type. In this human trial, fasting mimicking reduced the negative short term impact of chemotherapy on health, and, further, three to four times as many patients experienced a strongly beneficial response to the chemotherapeutic treatment. Extensive preclinical evidence suggests that short-term fasting and fasting mimicking diets (FMDs) can protect healthy cells against the perils of a wide variety of stressors, including chemotherapy, simultaneously rendering cancer cells more vulnerable to chemotherapy and other therapies. Essentially, fasting causes a switch in healthy cells from a proliferative state towards a maintenance and repair state. Malignant cells, in contrast, seem to be unable to enter this protective state because of oncoprotein activity, and therefore fail to adapt to nutrient scarce conditions. Instead, fasting deprives proliferating cancer cells of nutrients and growth factors, which renders them more sensitive to cancer therapy and increases cell ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs

Related Links:

Int J Clin Oncol. 2021 Aug 10. doi: 10.1007/s10147-021-02005-8. Online ahead of print.ABSTRACTPURPOSE: Numerous studies have suggested that metformin treatment can increase breast cancer survival; however, it is unclear whether its effects interact with intrinsic subtype or diabetic status. Therefore, we conducted a large nationwide study to assess this in women with surgically resected invasive breast cancer.METHODS: Patients with newly diagnosed breast cancer between 2007 and 2016 were identified using the national health insurance claims database of South Korea. Metformin or other drug exposures was defined as medicatio...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study assesses the risk of HR+/HER2- breast cancer with metformin-use in a dose- and intensity-dependent manner in postmenopausal women with type-2 diabetes mellitus (T2DM).
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: The impact of on-treatment glycemia on the efficacy of EVE-EXE therapy in HR+/HER2 aBC patients depends on baseline glycemia. This study lays the foundations for investigating novel therapeutic approaches to target the glucose/insulin axis in combination with PI3K/AKT/mTORC1 inhibitors in HR+/HER2 aBC patients.PMID:33785482 | DOI:10.1158/1078-0432.CCR-20-4928
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Our study shows a more favorable safety profile of s.c. versus i.v trastuzumab administration. The use of s.c. trastuzumab could be advisable in at-risk patients.PMID:33780903 | DOI:10.1016/j.breast.2021.03.004
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Alpelisib plus nab-paclitaxel combination was well-tolerated and shows encouraging efficacy, especially in patients with PIK3CA-mutated tumor/ctDNA. Impact of metabolic status on response to this combination merits further investigation.PMID:33602685 | DOI:10.1158/1078-0432.CCR-20-4879
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Alpelisib plus nab-paclitaxel combination was well-tolerated and shows encouraging efficacy, especially in patients with PIK3CA-mutated tumor/ctDNA. Impact of metabolic status on response to this combination merits further investigation. PMID: 33602685 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Dexamethasone | Diabetes | Diets | Endocrinology | Gastroschisis Repair | HER2 | Insulin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nutrition | Research | Toxicology